首页
国产噻托溴铵干粉剂治疗慢性阻塞性肺疾病的多中心随机对照临床试验
Efficacy and Safety of Tiotropium Bromide in the Treatment of Chronic Obstructive Pulmonary Disease——a Multi-center Randomized Clinical Trial
-
摘要: 目的 验证国产噻托溴铵干粉剂在中国慢性阻塞性肺疾病（COPD）患者中应用的有效性和安全性。方法 采用多中心、随机、阳性对照方法，试验组（n=109)给予噻托溴铵干粉剂18 μg吸入QD，对照组（n=111)为异丙托溴铵定量气雾剂40 μg吸入QID，疗程4周，考察指标为肺功能、临床症状及安全性。结果 试验组与对照组首剂给药后30 min及3 h一秒用力呼气容积（FEV1）较基线均增加（P<0.05)；试验组与对照组疗程结束后FEV1及用力肺活量（FVC）谷值较基线均增加（P<0.05)，增加程度试验组优于对照组（P<0.05)；试验组与对照组疗程结束后COPD症状评分较基线降低且试验组优于对照组（P<0.05)；治疗期间两组按需使用沙丁胺醇定量气雾剂的喷数差异无统计学意义。试验组用药后不良反应发生率（22.02%）与对照组（15.32%）相当（P=0.23）。结论 国产噻托溴铵干粉剂用于改善COPD患者肺功能和临床症状，安全有效，其长期疗效有待进一步验证。Abstract: Objective To investigate the efficacy and safety of domestic tiotropium inhalation capsule in patients with chronic obstructive pulmonary disease (COPD) with multi-center randomized clinical trial. Methods Patients with stable slight to moderate COPD were randomized into trial group (n=109) with tiotropium 18 μg Qd or control group (n=111) with ipratropium 40 μg Qid for a treatment of four weeks. The spirometry and scoring questionaire were recorded at different visits during the treatment. Rescue medication consumption and adverse events were recorded. Results Forced expiratory volume in 1 s (FEV 1) of both groups increased obviously 30 min and 3 h after first dosing. After four weeks treatments, FEV 1 and forced vital capacity (FVC) in both groups were improved obviously, and the improvement in tiotropium group was significantly higher than that ipratropium group. COPD symptom scores were significantly reduced in both groups, and the improvement in tiotropium group was significantly better than that in ipratropium group. There was no significant difference in rescue medication consumption between the two groups. The ratios of adverse events were 22.02% and 15.32% in tiotropium and ipratropium group, respectively (P=0.23). Conclusion Domestic tiotropium inhalation capsule is efficient and safe in the treatment of COPD.
-
-
期刊类型引用(12)
1. 郭文慧，原景，张炜. 益气活血化痰方治疗慢性阻塞性肺疾病稳定期疗效研究. 陕西中医. 2021(06): 721-723+738 . 
百度学术
2. 温志光. 噻托溴铵治疗COPD的效果及对生活质量的影响. 中国当代医药. 2018(02): 129-131 . 百度学术
3. 彭科营. 沙美特罗替卡松联合噻托溴铵治疗COPD并发重度支气管哮喘的临床效果观察. 中南医学科学杂志. 2017(06): 544-547 . 百度学术
4. 毛自芳. 吸入噻托溴铵干粉与异丙托溴铵定量气雾剂治疗慢性阻塞性肺疾病的疗效与安全性比较. 临床医药文献电子杂志. 2017(92): 18087-18088 . 百度学术
5. 黄杏雄. 硫酸沙丁胺醇气雾剂联合异丙托溴铵气雾剂治疗COPD合并呼吸衰竭的效果. 牡丹江医学院学报. 2017(02): 97-98 . 百度学术
6. 毛国富，陆建平. 沙丁胺醇气雾剂与异丙托溴铵气雾剂治疗COPD的观察及药学评价. 中国医药指南. 2017(21): 100-101 . 百度学术
7. 李彩霞，马忠英，吴昌归，李志奎，刘春涛，吴亚梅，郝青林，韩晓雯，章学毓. 苯环喹溴铵喷鼻剂治疗感冒后急性鼻炎的临床研究. 中国药房. 2017(05): 680-683 . 百度学术
8. 刘兴旺，刘兴盛. 噻托溴铵对老年慢性呼吸道疾病加重预防作用. 临床军医杂志. 2016(04): 427-429+433 . 百度学术
9. 谢建明. 噻托溴铵联合沙美特罗/氟替卡松对COPD患者症状改善的影响分析. 临床医药文献电子杂志. 2016(29): 5727-5729 . 百度学术
10. 颜小艳，周贤刚，周弋特，彭世秀. 国产噻托溴铵粉雾剂治疗慢性阻塞性肺疾病的临床疗效和成本分析. 四川医学. 2016(04): 426-429 . 百度学术
11. 余江清，丁月梅，卢志军. 药物干预对慢性阻塞性肺疾病合并症的临床研究. 中国当代医药. 2016(20): 21-24 . 百度学术
12. 裴斌. 沙丁胺醇气雾剂与异丙托溴铵气雾剂治疗COPD的临床疗效. 中国实用医药. 2016(22): 138-139 . 百度学术
其他类型引用(2)
计量
- 文章访问数: 2793
- HTML全文浏览量: 172
- PDF下载量: 31
- 被引次数: 14
下载:
